<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9953">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05686759</url>
  </required_header>
  <id_info>
    <org_study_id>GC5103-003_UDIV_P3b01</org_study_id>
    <nct_id>NCT05686759</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj.</brief_title>
  <official_title>A Phase 3b Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. in Post-liver Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GC Biopharma Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GC Biopharma Corp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of undiluted intravenous&#xD;
      infusion of I.V.-Hepabig inj. in post-liver transplant patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2023</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events occurred during clinical trials</measure>
    <time_frame>during 20 weeks post first Investigational product administration</time_frame>
    <description>Safety will be assessed throughout the study through clinical safety evaluations(Adverse events)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive rate of Hepatitis B Surface Antigen(HBsAg)</measure>
    <time_frame>Screening, 0 4, 8, 12, 16, and 20 weeks</time_frame>
    <description>Hepatitis B Surface Antigen(HBsAg) will be tested at every visit(V1~V7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatitis B Surface Antibody(Anti HBs) titer</measure>
    <time_frame>Screening, 0 4, 8, 12, 16, and 20 weeks</time_frame>
    <description>Hepatitis B Surface Antibody(Anti HBs) titer will be tested at every visit(V1~V7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of Hepatitis B e Antigen(HBeAg)</measure>
    <time_frame>Screening,0 4, 8, 12, 16, and 20 weeks</time_frame>
    <description>Hepatitis B e Antigen(HBeAg) will be tested at every visit(V1~V7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of Hepatitis B Virus DNA(HBV DNA)</measure>
    <time_frame>Screening, 0 4, 8, 12, 16, and 20 weeks</time_frame>
    <description>Hepatitis B Virus DNA(HBV DNA) will be tested at every visit(V1~V7)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Undiluted intravenous infusion of I.V.-Hepabig inj</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Undiluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit within approximately 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diluted intravenous infusion of I.V.-Hepabig inj</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diluted intravenous infusion of I.V.-Hepabig inj 10,000 International Unit into Dextrose 5% in water within approximately 1 hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Undiluted I.V.-Hepabig inj(GC5103)</intervention_name>
    <description>undiluted I.V.-Hepabig inj(GC5103) 10,000 International Unit</description>
    <arm_group_label>Undiluted intravenous infusion of I.V.-Hepabig inj</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Diluted I.V.-Hepabig inj(GC5103)</intervention_name>
    <description>Diluted I.V.-Hepabig inj(GC5103) 10,000 International Unit</description>
    <arm_group_label>Diluted intravenous infusion of I.V.-Hepabig inj</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥19 and ≤65 years at the time of signing the consent form&#xD;
&#xD;
          2. HBsAg(+) before liver transplantation&#xD;
&#xD;
          3. Subjects who had history of liver transplantation due to HBV-related end-stage liver&#xD;
             disease such as cirrhosis, liver cancer and fulminant hepatic failure and received&#xD;
             treatment for prevent hepatitis B recurrence&#xD;
&#xD;
          4. Subjects who have been received I.V.-Hepabig inj more than 3 times dose of&#xD;
             10,000International Unit/4weeks regimen, and whole duration of administration of&#xD;
             I.V.-Hepabig ing will not be exceeded 1 year while participating this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with history of anaphylaxis to any component of the investigational product&#xD;
&#xD;
          2. Pregnant or breast-feeding women&#xD;
&#xD;
          3. Deficiency of Immunoglobulin A&#xD;
&#xD;
          4. Clinically significant renal diseases (serum creatinine &gt;2.0mg/dL, anuria, renal&#xD;
             failure or on dialysis at screening)&#xD;
&#xD;
          5. Hemophilia&#xD;
&#xD;
          6. Co-infection with Hepatitis A Virus, Hepatitis C Virus, or Human Immunodeficiency&#xD;
             Virus&#xD;
&#xD;
          7. Subject with history of malignancy within the last 5 years (excluding primary liver&#xD;
             cancer)&#xD;
&#xD;
          8. Subject received estrogen or hormone replacement therapy within 3 months before&#xD;
             screening&#xD;
&#xD;
          9. HBsAg or HBeAg or HBV DNA positive at screening&#xD;
&#xD;
         10. Anti HBs titer less than below criteria at screening &lt;150 IU/L for subject whose HBeAg&#xD;
             and HBV DNA were negative(-) before liver transplantation &gt;500 IU/L for subject whose&#xD;
             HBeAg and HBV DNA were positive(+) before liver transplantation&#xD;
&#xD;
         11. Subject with history of drug abuse&#xD;
&#xD;
         12. Participated in another clinical study within 30 days (relative to the last dose of&#xD;
             investigational product) before screening&#xD;
&#xD;
         13. Subject who are determined disqualified to join clinical trials by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jayoung Shon</last_name>
    <phone>82-(0)31-260-1935</phone>
    <email>jyshon@gccorp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>December 2, 2022</study_first_submitted>
  <study_first_submitted_qc>January 9, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2023</study_first_posted>
  <last_update_submitted>February 13, 2023</last_update_submitted>
  <last_update_submitted_qc>February 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Liver Transplantation</keyword>
  <keyword>Hepatitis B Immunoglobulin</keyword>
  <keyword>Liver Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

